{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T05:01:11Z","timestamp":1695358871895},"reference-count":25,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"<jats:sec id=\"ab-eoi230043-4\"><jats:title>Importance<\/jats:title><jats:p>Sustained-release corticosteroids offer the potential of improved compliance and greater patient convenience for anti-inflammatory treatment after cataract surgery. However, they are substantially more expensive than postoperative corticosteroid eye drops, which have historically been standard care.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi230043-5\"><jats:title>Objective<\/jats:title><jats:p>To examine the use and cost of sustained-release corticosteroids in patients with Medicare who underwent cataract surgery in the US during the temporary pass-through reimbursement program period.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi230043-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This cross-sectional study examined Medicare fee-for-service (FFS) claims from beneficiaries with at least 12 continuous months of Medicare enrollment who underwent at least 1 cataract surgery from March 2019 through December 2021. Patients younger than 65 years, those with missing demographic information, those who had more than 1 cataract surgery on each eye, and those who received more than 1 corticosteroid on the day of surgery were excluded. Cataract surgeries with concurrent use of dexamethasone intraocular suspension 9% or dexamethasone ophthalmic insert were identified. Information on surgeon demographic characteristics and costs of surgery and drugs were extracted. Data were analyzed from June 15 to December 4, 2022.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi230043-7\"><jats:title>Exposure<\/jats:title><jats:p>Use of dexamethasone intraocular suspension 9% or dexamethasone ophthalmic insert during cataract surgery.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi230043-8\"><jats:title>Main Outcome Measures<\/jats:title><jats:p>Utilization rate and cost of dexamethasone intraocular suspension 9% and dexamethasone ophthalmic insert among Medicare FFS beneficiaries who underwent cataract surgery.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi230043-9\"><jats:title>Results<\/jats:title><jats:p>A total of 4\u202f252\u202f532 cataract surgeries in Medicare FFS beneficiaries (mean [SD] age, 74.8 [5.8] years; 1 730 811 male [40.7%] and 2 521 721 female [59.3%]) were performed by 12\u202f284 ophthalmologists (8876 male [72.3%], 2877 female [23.4%], and 531 sex unknown [4.3%]). In all, 34\u202f627 beneficiaries (0.8%) received dexamethasone intraocular suspension 9% and 73\u202f430 (1.7%) received a dexamethasone ophthalmic insert; the use of both drugs increased over the study period. The mean (SD) Medicare allowed charges for dexamethasone intraocular suspension 9% and dexamethasone ophthalmic insert were $531.47 ($141.52) and $538.49 ($63.79), respectively.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi230043-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>Despite offering the potential of improved compliance and greater patient convenience, findings of this study suggest that sustained-release corticosteroid use during cataract surgery was low and associated with cost increases to the health care system vs conventional postoperative eye drops. As these new products must be priced high enough to qualify for the Medicare pass-through program, unreasonable cost may have been a deterrent to their use, suggesting that the current Medicare reimbursement rules may not be appropriate for sustained-release postoperative corticosteroids in cataract surgery.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2023.3389","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T15:32:46Z","timestamp":1691076766000},"page":"844","source":"Crossref","is-referenced-by-count":1,"title":["Use and Cost of Sustained-Release Corticosteroids for Cataract Surgery Under the Medicare Pass-Through Program"],"prefix":"10.1001","volume":"141","author":[{"given":"Xi","family":"Dai","sequence":"first","affiliation":[{"name":"The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David F.","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of California, San Francisco, San Francisco"},{"name":"Altos Eye Physicians, Los Altos, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariel","family":"Chen","sequence":"additional","affiliation":[{"name":"The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland"},{"name":"Wills Eye Hospital, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Dun","sequence":"additional","affiliation":[{"name":"Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland"},{"name":"Department of Biomedical Informatics and Data Science, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safa","family":"Saeed","sequence":"additional","affiliation":[{"name":"School of Medicine, Aga Khan University, Karachi, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael X.","family":"Repka","sequence":"additional","affiliation":[{"name":"The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fasika Ambachew","family":"Woreta","sequence":"additional","affiliation":[{"name":"The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"11","key":"eoi230043r1","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.jcrs.2019.06.008","article-title":"Billing of cataract surgery as complex versus routine for Medicare beneficiaries.","volume":"45","author":"Zafar","year":"2019","journal-title":"J Cataract Refract Surg"},{"issue":"7","key":"eoi230043r2","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.jcrs.2007.03.053","article-title":"Incidence of cataract surgery from 1980 through 2004: 25-year population-based study.","volume":"33","author":"Erie","year":"2007","journal-title":"J Cataract Refract Surg"},{"issue":"12","key":"eoi230043r3","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/j.ophtha.2013.04.030","article-title":"Cataract surgery cost utility revisited in 2012: a new economic paradigm.","volume":"120","author":"Brown","year":"2013","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi230043r4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/00055735-200102000-00002","article-title":"Control of intra-ocular inflammation associated with cataract surgery.","volume":"12","author":"El-Harazi","year":"2001","journal-title":"Curr Opin Ophthalmol"},{"issue":"7","key":"eoi230043r5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010516.pub2","article-title":"Non-steroidal anti-inflammatory drugs versus corticosteroids for controlling inflammation after uncomplicated cataract surgery.","volume":"7","author":"Juthani","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"eoi230043r7","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.ophtha.2017.12.029","article-title":"Dexamethasone intracameral drug-delivery suspension for inflammation associated with cataract surgery: a randomized, placebo-controlled, phase iii trial.","volume":"125","author":"Donnenfeld","year":"2018","journal-title":"Ophthalmology"},{"issue":"2","key":"eoi230043r8","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jcrs.2018.09.023","article-title":"Multicenter randomized phase 3 study of a sustained-release intracanalicular dexamethasone insert for treatment of ocular inflammation and pain after cataract surgery.","volume":"45","author":"Tyson","year":"2019","journal-title":"J Cataract Refract Surg"},{"key":"eoi230043r9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2021.06.009","article-title":"Anti-inflammatory pharmacotherapy for the prevention of cystoid macular edema after cataract surgery.","volume":"232","author":"Taubenslag","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"eoi230043r10","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/ICU.0000000000000708","article-title":"Dropless cataract surgery: modernizing perioperative medical therapy to improve outcomes and patient satisfaction.","volume":"32","author":"Assil","year":"2021","journal-title":"Curr Opin Ophthalmol"},{"issue":"5","key":"eoi230043r14","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.ophtha.2019.11.005","article-title":"Prescribing patterns and costs associated with postoperative eye drop use in Medicare beneficiaries undergoing cataract surgery.","volume":"127","author":"Zafar","year":"2020","journal-title":"Ophthalmology"},{"issue":"3","key":"eoi230043r15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/IIO.0000000000000122","article-title":"Cataract drug delivery systems (dropless vs. nondropless cataract surgery).","volume":"56","author":"Rhee","year":"2016","journal-title":"Int Ophthalmol Clin"},{"issue":"4","key":"eoi230043r16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2155-9570","article-title":"Efficacy and safety of sustained release dexamethasone for the treatment of ocular pain and inflammation after cataract surgery: results from two phase 3 studies.","volume":"7","author":"Walters","year":"2016","journal-title":"J Clin Exp Ophthalmol"},{"issue":"10","key":"eoi230043r17","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/j.jcrs.2015.11.005","article-title":"Sustained-release dexamethasone for the treatment of ocular inflammation and pain after cataract surgery.","volume":"41","author":"Walters","year":"2015","journal-title":"J Cataract Refract Surg"},{"issue":"10","key":"eoi230043r18","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.jcrs.2018.07.015","article-title":"Safety of IBI-10090 for inflammation associated with cataract surgery: phase 3 multicenter study.","volume":"44","author":"Donnenfeld","year":"2018","journal-title":"J Cataract Refract Surg"},{"issue":"11","key":"eoi230043r19","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/j.jcrs.2014.02.037","article-title":"Evaluation of eyedrop administration by inexperienced patients after cataract surgery.","volume":"40","author":"An","year":"2014","journal-title":"J Cataract Refract Surg"},{"key":"eoi230043r21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1472-6963-12-56","article-title":"Adoption of new drugs by physicians: a survival analysis.","volume":"12","author":"Garj\u00f3n","year":"2012","journal-title":"BMC Health Serv Res"},{"issue":"10","key":"eoi230043r22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0204826","article-title":"Influence of peer networks on physician adoption of new drugs.","volume":"13","author":"Donohue","year":"2018","journal-title":"PLoS One"},{"key":"eoi230043r24","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2147\/PPA","article-title":"Evaluating the patient experience after implantation of a 0.4 mg sustained release dexamethasone intracanalicular insert (Dextenza\u2122): results of a qualitative survey.","volume":"11","author":"Gira","year":"2017","journal-title":"Patient Prefer Adherence"},{"issue":"3","key":"eoi230043r25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00055735-199706000-00003","article-title":"Treatment of cytomegalovirus retinitis with the intraocular ganciclovir implant.","volume":"8","author":"Anand","year":"1997","journal-title":"Curr Opin Ophthalmol"},{"key":"eoi230043r6","unstructured":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Application number: 208912Orig1s000 summary review for NDA 208912 Dexycu (dexamethasone intraocular suspension) 0.9%. February 8, 2018. Accessed July 27, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/208912Orig1s000SumR.pdf"},{"key":"eoi230043r11","unstructured":"Centers for Medicare & Medicaid Services. Research Data Assistance Center. Accessed December 30, 2022. https:\/\/resdac.org\/"},{"key":"eoi230043r12","unstructured":"US Centers for Medicare & Medicaid Services. National downloadable file. Accessed December 30, 2022. https:\/\/data.cms.gov\/provider-data\/dataset\/mj5m-pzi6?"},{"key":"eoi230043r13","unstructured":"Centers for Medicare & Medicaid Services. Research Data Assistance Center: Medicare Data on Provider Practice and Specialty (MD-PPAS). Accessed December 30, 2022. https:\/\/resdac.org\/cms-data\/files\/md-ppas"},{"key":"eoi230043r20","unstructured":"Centers for Medicare & Medicaid Services. Title 42 chapter IV subchapter A part 419 subpart G transitional pass-through payments. Accessed December 30, 2022. https:\/\/www.govinfo.gov\/content\/pkg\/CFR-2007-title42-vol3\/html\/CFR-2007-title42-vol3-part419-subpartG.htm"},{"key":"eoi230043r23","unstructured":"Centers for Medicare & Medicaid Services. Drug coverage (Part D). Accessed January 16, 2023. https:\/\/www.medicare.gov\/drug-coverage-part-d"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2807966\/jamaophthalmology_dai_2023_oi_230043_1694029125.44626.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T15:02:58Z","timestamp":1695308578000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2807966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2023.3389","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,1]]}}}